An exploration of Eisai’s EMEA Knowledge Centre
Eisai is a global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas. Its UK facility, known
8 min read
Interview with George Fraser-Harding of Aviva Investors
We spoke with George Fraser-Harding, head of European Funds at Aviva Investors, about life sciences real estate. Aviva Investors has
4 min read
Interview with Artem Korolev of Mission Street
Mission Street is a specialist investor, developer and operator for the science and innovation sector. The company’s science and
4 min read
Oslo Cancer Cluster Incubator: from offices to shared labs
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating
2 min read
Interview with Karolina Karl of Invest Lithuania
We caught up with Karolina Karl who leads the life sciences team at Invest Lithuania, the country’s inward investment
3 min read
Sale and leaseback deals: pros and cons for owner-occupiers and investors
If a company’s core business can generate profits of 15 per cent to 20 per cent, it makes sense to allocate capital into the core business and away from real estate, where returns are likely to be in the 6% to 8% range.
9 min read